Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.51, denoting a -0.44% change from the preceding trading day.
JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges
J&J's JNJ stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity of its blockbuster drug, Stelara, and uncertainty around the talc lawsuits, among others.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference
Johnson & Johnson (NYSE:JNJ ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ET Corporate Participants Joe Wolk - EVP, Chief Financial Officer Conference Call Participants Shagun Singh - RBC Capital Markets Shagun Singh Hello everyone, I am Shagun Singh, Senior Research Analyst at RBC, and I'm very happy to host the next session with Johnson & Johnson. Joining us from the company is Joe Wolk, Chief Financial Officer of the company.
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
If You Invested $25,000 In Johnson & Johnson (JNJ) 20 Years Ago, This Is How Much Cash From Dividends You Would Have Today
Companies with strong products, good management, solid earnings and growth trends, and a history of annual dividend increases are often popular buy and hold stocks to take advantage of dividend compounding.
Why Is Johnson & Johnson (JNJ) Down 4.9% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript
Johnson & Johnson (NYSE:JNJ ) BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ET Company Participants John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Tim Anderson - Bank of America Tim Anderson I think we're live. Thank you for joining us.
Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes
The U.S. and China have agreed to reduce tariffs temporarily for 90 days. I expect continued market volatility in the negotiation process. Johnson & Johnson could offer some immunity due to the specific breakdown of the trade between these two countries and JNJ's relatively minor exposure to China.
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?
Both JNJ and ABBV expect their sales and profits to improve in 2025.
